Release Date: 18-Sep-2024
Initially identified as a negative regulator of T cell activation, VISTA, also known as PD-1H (Programmed Cell Death 1 Homolog), has emerged as a promising therapeutic target in cancer immunotherapy due to its complex role in modulating immune responses within the tumor microenvironment. VISTA is a member of the B7 family of immune checkpoint proteins. Albeit, no VISTA therapy has been approved into the market; however, it is anticipated that a newfangled drug will penetrate into market in upcoming 10-15 years as evident from preclinical as well as clinical trials.
Download Report:
For the indication of cancer, VISTA is predominantly expressed on myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), dendritic cells, and certain subsets of T cells. Its expression is often upregulated in various types of cancer, including melanoma, lung cancer, breast cancer, and colorectal cancer. The overexpression of VISTA contributes to immune evasion mechanisms employed by tumors, dampening T cell activation and promoting an immunosuppressive tumor microenvironment. Functionally, VISTA interacts with its receptor(s), including an unidentified ligand or potentially multiple ligands, to exert its immunosuppressive effects. It inhibits T cell proliferation and cytokine production, induces T cell apoptosis, and promotes the differentiation of regulatory T cells (Tregs). These mechanisms collectively contribute to the suppression of anti-tumor immune responses and facilitate tumor immune escape.
The role of VISTA in cancer extends beyond its direct effects on T cells. It also influences the function of myeloid cells within the tumor microenvironment. For instance, VISTA expression on MDSCs and TAMs promotes their immunosuppressive phenotype, allowing these cells to suppress effector T cell function and support tumor growth and metastasis. Furthermore, VISTA has additionally being discovered in autoimmune, allergic, viral and many other disorder as per the research studies conducted by Sichuan University along with other universities.
Given its immunosuppressive role, targeting VISTA has emerged as a promising strategy to enhance anti-tumor immunity and improve clinical outcomes in cancer patients. Preclinical studies using VISTA-blocking antibodies or genetic knockout models have shown promising results in various cancer types. These studies demonstrate that blocking VISTA can enhance T cell-mediated anti-tumor immune responses, reduce tumor burden, and prolong survival in animal models.
In clinical settings, the therapeutic potential of VISTA blockade is being actively investigated. Monoclonal antibodies targeting VISTA are being developed and evaluated in early-phase clinical trials as monotherapy or in combination with other immunotherapies, such as anti-PD-1/PD-L1 antibodies or chemotherapy. These trials aim to assess the safety, efficacy, and optimal dosing regimens of VISTA-targeted therapies in patients with advanced solid tumors and hematological malignancies.
One of the key advantages of targeting VISTA lies in its potential to complement existing immunotherapies, such as PD-1/PD-L1 blockade. While PD-1/PD-L1 inhibitors primarily target the adaptive immune checkpoint pathway, VISTA blockade targets complementary mechanisms of immune suppression within the tumor microenvironment. This dual targeting approach could potentially overcome resistance to single-agent checkpoint blockade and enhance the durability of anti-tumor immune responses.
The clinical development of VISTA-targeted therapies faces several challenges, including identifying predictive biomarkers to select patients who are most likely to benefit, managing potential immune-related adverse events, and optimizing combination strategies with other cancer treatments. Addressing these challenges requires a deep understanding of the complex interplay between VISTA and the immune system in cancer.
In conclusion, VISTA represents a critical immune checkpoint regulator with significant implications for cancer immunotherapy. Its overexpression in the tumor microenvironment contributes to immune evasion and poor clinical outcomes in cancer patients. Targeting VISTA holds promise as a novel therapeutic strategy to restore anti-tumor immune responses and improve patient outcomes. Once one VISTA drug will enter into market will open novel opportunities in imminent years.